CTRI/2023/12/060590进行中（未招募）3 期
A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) - Commute-p
F HoffmannLa Roche Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Body weight more than 5 kg at screening.
- •Vaccination against Neisseria meningitis serotypes A, C, W, and Y; vaccination against serotype B, according to national vaccination recommendations.
- •Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae, according to national vaccination recommendations.
- •For participants receiving other therapies (e.g. immunosuppressants, corticosteroids, mTORi, or calcineurin inhibitors: stable dose for more than 28 days prior to screening and up to the first crovalimab administration.
- •For female participants of childbearing potential: an agreement to remain abstinent or use contraception.
- •Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant.
- •Onset of initial TMA presentation within 28 days prior to the first dose of crovalimab (for Naive Cohort only).
- •Documented treatment with either eculizumab or ravulizumab (for Switch Cohort only).
- •Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).
- •Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP participants in the Pretreated Cohort only).
- •Known C5 polymorphism (for C5 SNP participants in the Pretreated Cohort only).
排除标准
- •TMA associated with non-aHUS related renal disease.
- •Positive direct Coombs test.
- •Chronic dialysis and/or end stage renal disease.
- •Identified drug exposure-related TMA.
- •Presence or history of a condition that could trigger TMA, such as malignancy, bone marrow or organ transplant (other than kidney transplant) or autoimmune disease.
- •History of a kidney disease, other than aHUS.
- •History of Neisseria meningitidis infection within 6 months of study enrollment.
- •Known or suspected immune deficiency (e.g., history of frequent recurrent infections).
- •Positive HIV test.
- •Active systemic bacterial, viral, or fungal infection within 14 days before first crovalimab administration.
- •Presence of fever (more than 38 degrees celsius) within 7 days before the first crovalimab administration.
- •Multi-system organ dysfunction or failure.
- •Recent IVIg treatment.
- •Pregnant or breastfeeding or intending to become pregnant.
- •Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater.
- •Recent use of tranexamic acid.
- •Current or previous treatment with a complement inhibitor (for Naive Cohort only).
- •First initiation of plasma exchange/plasma infusions (PE/PI) not more than 28 days prior to first crovalimab administration (for Naive Cohort only).
- •PE/PI should not be administered within 6 hours of first crovalimab administration (for Naive Cohort only).
- •Receiving PE/PI within 8 weeks of the first crovalimab administration (Switch Cohort only).
- •Positive for active Hepatitis B and/or C infections (HBV/HCV) (for Switch Cohort and switching C5 SNP Pretreated Cohort participants who recently received C5 inhibitor treatment).
- •Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
- •Documented condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect and TMA related to Diacylglycerol kinase e (DGKE) nephropathy.
研究者
相似试验
招募中
3 期
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic SyndromeJPRN-jRCT2041210086Mona D. Shah45
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)EUCTR2020-002475-35-HUF. Hoffmann-La Roche Ltd90
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic Syndrome (aHUS)MedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 100000004851EUCTR2020-002437-15-HUF.Hoffmann-La Roche Ltd35
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic Syndrome (aHUS)MedDRA version: 20.1Level: LLTClassification code 10079841Term: Atypical hemolytic uremic syndromeSystem Organ Class: 100000004851EUCTR2020-002437-15-BEF.Hoffmann-La Roche Ltd45
尚未招募
3 期
A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY,PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME(aHUS)D593 Haemolytic-uraemic syndromeHaemolytic-uraemic syndromeD593PER-019-21F. HOFFMANN-LA ROCHE LTD.